News

Treatment with KER-012, an experimental therapy Keros Therapeutics is developing to treat pulmonary arterial hypertension (PAH), lowered markers of heart damage, fibrosis, and inflammation in a Phase 1 clinical trial that tested the therapy in healthy postmenopausal women. Keros presented the findings at the American Thoracic Society (ATS)…

The proportion of people with pulmonary arterial hypertension (PAH) who start on a combination of medications after they’re diagnosed is low, but has increased over the last decade, a study shows. The findings were presented at the 2023 American Thoracic Society (ATS) International Conference, in the poster, “…

Team PHenomenal Hope will host its inaugural symposium — PHenomenal Hope 2023: Knowledge, Research & Advocacy in PH — on Dec. 15 in Boston, allowing renowned experts, young researchers, and healthcare providers to share efforts on pulmonary hypertension (PH) clinical research and care. “Team PHenomenal Hope has grown…

People with pulmonary arterial hypertension (PAH) and their caregivers place different value on the parameters used to evaluate clinical worsening in trials, according to the findings of a survey in Canada. Patients attributed significant importance to lacking clinical improvement, needing long-term oxygen therapy, and any decrease in health-related quality…

MRE-269, an active metabolite of Uptravi (selexipag), is more effective at stopping the growth of lung cells from people with chronic thromboembolic pulmonary hypertension (CTEPH) than it is in healthy lung cells, a study found. Researchers also discovered that MRE-269 may do this by increasing the activity of ID1…

Gossamer Bio is planning to soon launch a Phase 3 clinical trial to test its experimental inhaled therapy seralutinib (GB002) in people with pulmonary arterial hypertension (PAH). “We remain on track to begin our Phase 3 clinical trial of seralutinib in the coming months, moving one step closer…

Members from two families with diagnosed or suspected pulmonary arterial hypertension (PAH) each carried two copies of mutations that map to the CAPNS1 gene and are likely rare causes of the disease, according to a study. The study, “Biallelic variants in the calpain regulatory subunit CAPNS1 cause pulmonary…

More than half of people with pulmonary hypertension (PH) may experience symptoms during sexual activity, such as difficulty breathing (dyspnea), heart palpitations, and chest pain, a small study found. However, around 2 in 3 patients don’t consider it important to bring up the topic of sexuality to their…

Treatment with levosimendan — a medication seen to improve cardiac function — was associated with rapid clinical benefits in preterm infants with heart problems and pulmonary hypertension (PH), a study in Germany reports. The response to treatment was independent of the babies’ birth weight and how far along…

Molecular differences are evident between infants with severe bronchopulmonary dysplasia (BPD) and pulmonary hypertension (PH) and those with severe BPD but not PH, a pilot study that used an integrated analysis of gene activity and protein production reported. PH is a common complication of BPD, a breathing disorder in…

Infants with persistent pulmonary hypertension of the newborn (PPHN) who have blood type O responded better to inhaled nitric oxide (iNO) vasodilator therapy than those with other blood types, a small study reported. PPHN newborns with blood type A showed a similar response to type O newborns, while the…

Many people with pulmonary arterial hypertension (PAH) report better mental and physical health following the start of the COVID-19 pandemic, a study found. “Unexpectedly, we found that some objective measures of pulmonary hypertension disease severity actually improved during the COVID-19 pandemic. This included longer 6-minute walk distances, lower NT-proBNP…